|
| Interacted pairs | (% per total number of detected interactions) | Severity | Effect | Possible mechanism |
|
| Ranitidine HCl+meperidine HCl | 158 (14.2%) | Major | Prolongation of opioid effects | Inhibition of meperidine metabolism |
| Bisoprolol fumarate+aspirin | 81 (7.3%) | Moderate | Increased blood pressure | Decreased production of renal prostaglandins |
| Aspirin+furosemide | 66 (5.9%) | Major | Reduced diuretic effectiveness and possible nephrotoxicity | Decreased renal prostaglandin synthesis |
| Clopidogrel+atorvastatin calcium | 60 (5.4%) | Moderate | High on-treatment platelet reactivity | Competition with CYP3A4-mediated clopidogrel metabolism |
| Ciprofloxacin+metronidazole | 54 (4.8%) | Major | QT prolongation and arrhythmias | QT prolongation |
| Warfarin sodium+acetaminophen | 51 (4.6%) | Moderate | Increased risk of bleeding | Inhibition of warfarin metabolism |
| Ranitidine hydrochloride+aspirin | 31 (2.8%) | Minor | Reduced salicylate plasma levels and decreased antiplatelet effect of aspirin | Reduced absorption of aspirin |
| Phenytoin+ranitidine hydrochloride | 20 (1.8%) | Minor | Increased phenytoin concentrations | Decreased phenytoin metabolism |
|
